EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Safety and pharmacokinetic properties of a new formulation of parenteral artesunate in healthy Thai volunteers

Joel Tarning, Borimas Hanboonkunupakarn, Richard M Hoglund, Kesinee Chotivanich, Mavuto Mukaka, Sasithon Pukrittayakamee, Nicholas P J Day, Nicholas J White, Arjen M Dondorp, Podjanee Jittamala

Malaria Journal · 03.10.2024 · 23 (1)

DOI: 10.1186/s12936-024-05085-9 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Malaria Journal, online erschienen am 03.10.2024. Verfasst von Joel Tarning und 9 weiteren Autor:innen. Beteiligte Einrichtung: Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok, 10400, Thailand. Hauptthemen laut MEDLINE: Artesunate, Antimalarials, Artemisinins, Cross-Over Studies. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Parenteral artesunate is the first-line therapy for severe malaria. Artesunate, in its current formulation, must be prepared immediately before administration by first dissolving in sodium bicarbonate solution and then diluting in saline. A novel solvent for rapid and stable single step reconstitution of artesunate was recently developed showing improved solubility and stability. This study aimed to compare the safety and pharmacokinetic properties of the currently available and newly developed parenteral formulation of artesunate in healthy Thai volunteers.

Methods

This was an open-label, randomized, 4 periods, 4-treatments, 24-sequence, single-dose, cross-over study in 72 male and female healthy Thai volunteers. Frequent pharmacokinetic samples were collected in all volunteers at each dose occasion. Observed concentration–time profiles were analysed with a non-compartmental approach followed by a bioequivalence evaluation.

Results

Both intramuscular and intravenous administrations of the new parenteral formulation of artesunate were safe and well-tolerated, with no additional safety signals compared to the currently used formulation. The pharmacokinetic properties of artesunate and its active metabolite, dihydroartemisinin, were well-characterized, and showed rapid conversion of artesunate into dihydroartemisinin. Intramuscular administration of the newly formulated artesunate resulted in almost complete bioavailability of dihydroartemisinin. The pharmacokinetic properties were similar between the old and new formulation.

Conclusions

The new and more easily prepared formulation of artesunate was safe and well-tolerated, with similar pharmacokinetic properties compared to the currently used formulation. Dihydroartemisinin, the active metabolite responsible for the majority of the anti-malarial effect, showed equivalent exposure after both intravenous and intramuscular administration of artesunate, suggesting that both routes of administration should generate comparable therapeutic effects.

Trial registration

The study was registered to clinicaltrials.gov (#TCTR20170907002).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ArtesunateAntimalarialsArtemisininsCross-Over StudiesHealthy VolunteersHumansMaleAdultFemaleThailandYoung AdultInjections, IntramuscularAdministration, IntravenousMiddle AgedAdolescentTherapeutic EquivalencySoutheast Asian People

Stichwörter der Autor:innen

ArtesunateBioequivalenceFormulationHealthy volunteerIntramuscularIntravenousMalariaPharmacokinetics

Substanzen

ArtesunateAntimalarialsArtemisinins

Autor:innen und Institutionen

  • Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok, 10400, Thailand.
  • Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • The Royal Society of Thailand, Dusit, Bangkok, Thailand.
  • Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok, 10400, Thailand. podjanee@tropmedres.ac.
  • Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. podjanee@tropmedres.ac.

Förderung

  • Wellcome Trust

Zitieren

APA

Tarning, J., Hanboonkunupakarn, B., Hoglund, R. M., Chotivanich, K., Mukaka, M., Pukrittayakamee, S., Day, N. P. J., White, N. J., Dondorp, A. M., & Jittamala, P. (2024). Safety and pharmacokinetic properties of a new formulation of parenteral artesunate in healthy Thai volunteers. Malaria Journal, 23(1). https://doi.org/10.1186/s12936-024-05085-9

Vancouver

Tarning J, Hanboonkunupakarn B, Hoglund RM, Chotivanich K, Mukaka M, Pukrittayakamee S, et al. Safety and pharmacokinetic properties of a new formulation of parenteral artesunate in healthy Thai volunteers. Malaria Journal. 2024;23(1). doi:10.1186/s12936-024-05085-9

BibTeX
@article{Tarning2024,
  author = {Tarning, Joel and Hanboonkunupakarn, Borimas and Hoglund, Richard M and Chotivanich, Kesinee and Mukaka, Mavuto and Pukrittayakamee, Sasithon and Day, Nicholas P J and White, Nicholas J and Dondorp, Arjen M and Jittamala, Podjanee},
  title = {Safety and pharmacokinetic properties of a new formulation of parenteral artesunate in healthy Thai volunteers},
  journal = {Malaria Journal},
  year = {2024},
  volume = {23},
  number = {1},
  doi = {10.1186/s12936-024-05085-9}
}
Kostenlos starten →